Atlas Trials

High-Dose Gemcitabine, Busulfan, and Thiotepa Followed by ASCT in Primary Central Nervous System Lymphoma

Clinical trial NCT07014943 · RECRUITING

Trial details

NCT number
NCT07014943
Sponsor
Sichuan University
Status
RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Primary Central Nervous System Lymphoma (PCNSL)
Start date
2022-01-01
Primary completion
2026-12-31
Enrollment
34

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.